Gastric and esophageal cancers were the fifth and tenth most common cancers diagnosed in Europe in 2006 and the fourth and ninth most common causes of death from cancer, respectively [1] . Surgery alone is no longer an accepted practice for any but the earliest stage disease, or for patients in whom there are contraindications to combined modality therapy, but there remains no international consensus as to the optimal peri-operative management of gastro-esophageal cancers. Large randomized controlled trials (RCTs) have attempted to define gold-standard treatment, but data comparing different treatment strategies such as peri-operative chemotherapy with adjuvant chemoradiation (CRT) for gastric cancer or neoadjuvant chemotherapy versus CRT for esophageal adenocarcinomas are still awaited. Additionally, the emergence of targeted agents such as the anti-vascular endothelial growth factor (VEGF) monoclonal antibody, bevacizumab, the epidermal growth factor receptor (EGFR) antibodies cetuximab and panitumumab and possibly tyrosine kinase inhibitors (TKIs), are likely to further change the way that operable gastro-esophageal cancers are managed.
peri-operative management of gastric cancer adjuvant chemotherapy: Japanese data
The rationale for adjuvant chemotherapy is to eradicate micrometastases, to reduce the risk of distant relapse and improve outcome. A survival benefit from adjuvant chemotherapy for resected gastric cancer was first suggested by a trial published in 1977 [2] of 249 patients, randomized to receive surgery with or without adjuvant oral 5-fluorouracil (5-FU) and FT-207, a derivative of 5-FU, for 24-36 months. A statistically significant increase in 2-year survival was demonstrated (P < 0.05), but this was not maintained at 3 years. The data were not practice changing outside Japan, but paved the way for further trials. A larger phase III study [3] of 496 patients, randomized to receive surgery with or without adjuvant mitomycin C (MMC) for 5 weeks, failed to demonstrate an overall survival benefit in the intent-to-treat (ITT) population. On subset analysis, an adverse effect on survival from adjuvant chemotherapy in patients with early-stage disease, but an enduring survival advantage in those with moderately advanced lymph-node or serosal involvement (>T2) was seen. Despite these trends, the Japanese Gastric Cancer Surgical Study Group (JCSSG) further investigated adjuvant chemotherapy in serosa-negative (T1-2) gastric cancer [4, 5] , with both trials showing no significant benefit, although the 5-year survival rates were impressive at >80%. More recently, using the oral fluoropyrimidine uracil-tegafur (UFT), the JCSSG demonstrated a significant survival benefit [6] in 190 patients with T2N1-2 disease randomized to surgery with or without adjuvant chemotherapy for 16 months. The 5-year survival was 73% in the control arm and 86% in the treatment arm (P = 0.017). Equally, investigators using the novel oral fluoropyrimidine S-1 (tegafur combined with the enzyme inhibitors gimeracil and oteracil), reported a 10% increase in 3-year survival from 70.1% to 80.5% (P = 0.0024) in 1059 patients with resected stage Ib-IV disease [7] . Of note, 54% of patients had T2 tumors and only 2% had T4 tumors; a different distribution to that seen in Western trials. Surgery with D2 resection and an adjuvant oral fluoropyrimidine is now the standard of care for Japanese patients with stage II/III gastric cancer but the survival rates have been difficult to replicate in unselected Western populations (Table 1) .
adjuvant chemotherapy: Western data
The results of Western trials of adjuvant chemotherapy have been largely disappointing. The phase III European Organization for Treatment of Cancer (EORTC) trial of 314 patients with resected stage II/III gastric cancer randomized to surgery with or without adjuvant FAM chemotherapy (5-FU, doxorubicin and MMC) [9] failed to meet the primary endpoint of a difference in overall survival. Although timeto-progression was significantly prolonged in the experimental arm (P = 0.02), severe toxicity was a problem; therefore this regimen was largely abandoned. The phase III Southwest Oncology Group (SWOG) trial of adjuvant FAM chemotherapy symposium article published the same year [10] did not encounter the same problems with toxicity, but again failed to demonstrate any significant benefit. A small randomized Spanish study [11] achieved its primary endpoint, demonstrating an improvement in 5-year overall survival from 36% to 56% (P = 0.04) in patients with resected stage III gastric cancer treated with adjuvant MMC and oral tegafur, over those treated with surgery alone. However, with only 148 patients randomized, the trial was too small to be practice changing in light of previous negative data. A larger Italian study [12] was unable to support these data using etoposide, doxorubicin and cisplatin (EAP) followed by 5-FU and folinic acid in patients with poor prognosis resected gastric cancer and a French trial [13] of adjuvant cisplatin and 5-FU (CF), again failed to demonstrate a significant survival benefit. Adjuvant chemotherapy with 5-FU, doxorubicin or epirubicin, methotrexate and leucovorin (FAMTX or FEMTX) proved even less successful; with a non-significant reduction in survival of patients with resected adenocarcinoma of the stomach or esophago-gastric junction (OGJ) in the combined analysis of two Italian phase III trials [14] . A meta-analysis of 21 trials of adjuvant chemotherapy for resectable gastric cancer [15] showed a significant overall benefit for chemotherapy (odds ratio 0.84, 95% confidence interval (CI) 0.74-0.96] which was lost when the analysis was limited to Western groups (odds ratio 0.96, 95% CI 0.83-1.12) ( Table 1) . 
adjuvant CRT
The Intergroup 0116 trial [16] was the first Western data to show a practice-changing benefit for adjuvant therapy in resected gastric cancer, using CRT to enhance local and systemic control. A total of 556 patients with completely resected adenocarcinoma of the stomach or OGJ were randomized to adjuvant 5-FU and leucovorin (5-FU/LV)-based CRT or observation. The primary endpoint of the trial was met, with an increase in median survival from 27 months in the control arm to 36 months in the experimental arm (P = 0.005). However, toxicity from the regimen was not insignificant, with three toxic deaths (1%), 41% grade 3 toxicity and 32% grade 4 toxicity. Following presentation of the data in 2001, adjuvant CRT became a widely accepted practice, although the trial received criticism for the quality of the surgery included: although D2 resection was recommended, only 10% of patients underwent this extent of surgery, with a further 36% undergoing D1 resection and 54% undergoing D0 resection only. This led to debate as to whether the radiotherapy had compensated for inadequate surgery, and hence, whether it is unnecessary after a D2 resection. However, the investigators reported no significant difference in the outcome of patients, in terms of disease-free or overall survival, by level of dissection (P = 0.80).
There are phase II data to suggest that adjuvant CRT might be optimized by the addition of cisplatin and possibly paclitaxel [17] , but confirmatory phase III data are awaited.
peri-operative chemotherapy
Potential advantages of a neo-adjuvant approach include tumor down-staging to allow a higher proportion of R0 resections and, ensuring that more patients receive systemic therapy due to better tolerance of pre-operative than postoperative therapy. Other advantages may include early treatment of distant micro-metastases and relief of diseaserelated symptoms. However, potential disadvantages include toxicity from chemotherapy which could delay or even prevent surgery, or increase the risk of post-operative complications. Also, patients may develop progressive disease whilst on chemotherapy and hence compromise their tumor resection, although this may reflect the aggressive biology of their disease and indicate a poorer prognosis with or without surgery. One solution to this is the use of early response evaluation, so that non-responders can be detected before their disease becomes inoperable. Two recent phase II trials [18, 19] have demonstrated the potential value of positron emission tomography (PET) scanning in this context; the larger of which included 110 patients with locally advanced carcinoma of the OGJ [18] and found that metabolic response measured by PET scanning after 2 weeks of neo-adjuvant platinum and fluorouracil-based chemotherapy is predictive of survival; median survival had not been reached in the 54 metabolic-responders who had a further 12 weeks of chemotherapy before 50 then proceeded to surgery, versus 25.8 months in the 56 non-responders, of whom 54 had proceeded immediately to surgery [hazard ratio (HR) 2.13, 95% CI 1.14-3.99, P = 0.015]. Similar results were reported from a phase II trial using neo-adjuvant CRT for patients with operable esophageal cancer [20] .
Data from the Dutch Gastric Cancer Group Study of surgery with or without neo-adjuvant FAMTX for operable gastric cancer [21] was due to be combined for analysis with the data from the UK Medical Research Council (MRC) Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial [22] , but the Dutch trial closed early due to poor accrual and inadequate efficacy demonstrated at the interim analysis; follow-up of 59 patients showed a non-significant reduction in median survival from 30 months in the surgery-alone group to 18 months in the FAMTX group. However, this is likely to be a failure of the chemotherapy regimen, as FAMTX has been demonstrated to be an inferior combination regimen in advanced gastric cancer [23] . In contrast, the MAGIC trial [22] demonstrated a clear survival advantage from peri-operative chemotherapy over surgery alone for adenocarcinoma of the stomach, OGJ or lower esophagus. A total of 503 patients were randomized to receive pre-operative chemotherapy, with three cycles of epirubicin, cisplatin and infused 5-FU (ECF) followed by surgery and a further three cycles of adjuvant ECF, or resection alone. The study met its primary endpoint of overall survival, demonstrating a statistically significant increase from 23% to 36% (P = 0.009). A significant down-staging effect of chemotherapy was also demonstrated, with 51.7% versus 36.8% T1-2 tumors at surgery. Only 91.6% of patients in the chemotherapy arm proceeded to surgery, compared with 96.4% in those assigned to surgery alone, although a higher percentage of operations were curative in the experimental arm (69.3% versus 66.4%). Importantly, the rates of post-operative complication and death were not increased by the neo-adjuvant chemotherapy and the regimen was generally well tolerated. Neo-adjuvant therapy was completed in 86% of those randomized, but only 54.8% even commenced adjuvant therapy and only 41.6% received all six cycles. However, it was impossible to determine whether the survival advantage was due solely to the neo-adjuvant chemotherapy or whether patients who received adjuvant therapy gained additional benefit.
The peri-operative strategy was supported by data from the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC) ACCORD07-FFCD 9703 trial [24] of neo-adjuvant 5-FU and cisplatin (CF) for patients with resectable adenocarcinoma of the stomach, OGJ or lower esophagus. Post-operative chemotherapy was recommended for patients who had responded to pre-operative chemotherapy and those with node-positive disease who had stable disease after chemotherapy. Of patients randomized to the treatment arm, 86.7% completed at least two cycles of neo-adjuvant chemotherapy with 47.8% of those randomized going on to receive adjuvant therapy. The overall survival reported in the 224 patients randomized was 24% in the control arm and 38% in the treatment arm (P = 0.02). The R0 resection rate was also significantly increased from 73% to 84% by neo-adjuvant chemotherapy (P = 0.04) ( Table 2) .
Peri-operative chemotherapy is now standard practice in many countries and provides an alternative to adjuvant CRT. The Dutch Colorectal Cancer Group's CRITICS study, a phase III trial of adjuvant chemotherapy with epirubicin, cisplatin Annals of Oncology symposium article and capecitabine (ECX) or CRT with cisplatin and capecitabine in resectable gastric cancer, which includes three cycles of ECX chemotherapy pre-operatively in both arms, may provide an answer as to which strategy is superior. The new MRC ST03 trial adds the anti-angiogenic monoclonal antibody bevacizumab to peri-operative ECX for resectable stage Ib-IV, Type III OGJ and gastric cancer and opened to recruitment in 2007. The trial is aiming to recruit 1100 patients over 3 years and is evaluating the safety of the combination, as well as being powered to detect an overall survival benefit (Table 3) .
peri-operative management of esophageal cancer neo-adjuvant chemotherapy
The first large RCT of neo-adjuvant chemotherapy for operable esophageal cancer failed to show significant benefit; the United States Intergroup trial [25] randomized 440 patients to surgery alone (n = 227) or three cycles of chemotherapy with cisplatin (100 mg/m 2 day 1) and 5-FU (1000 mg/m 2 /day days 1-5) every 28 days before resection (n = 213). Patients who responded to chemotherapy were offered two cycles of adjuvant therapy with a reduced dose of cisplatin (75 mg/m 2 ). There was no significant difference between the R0 resection rate in each arm of the trial (59% surgery alone, 62% chemotherapy), postoperative mortality (6% both arms), or median survival (16.1 months for surgery alone and 14.9 months for the experimental arm, HR 1.07, 95% CI 0.87-1.32, P = 0.49). Toxicity, especially neutropenia and mucositis (grade ‡3 in 29%), was a problem in the chemotherapy arm, with 2% of patients dying from chemotherapy-related causes, mainly neutropenic sepsis; which may have confounded the results. In contrast, the MRC's larger OE02 trial [26] demonstrated a survival benefit from neoadjuvant chemotherapy for resectable esophageal cancer of any cell type. A total of 802 patients were randomized to receive a less intense regimen of two cycles of cisplatin (80 mg/m 2 day 1) plus infusional 5-FU (1000 mg/m 2 /day days 1-4) followed by resection, or resection alone. Post-operative complications were comparable in the two treatment arms (41% and 42%, respectively) and disease-free (P = 0.0014) and overall (P = 0.004) survival were significantly prolonged (median survival 13.3 months control arm, 16.8 months treatment arm, HR 0.79, 95% CI 0.67-0.93). The greater intensity of the chemotherapy regimen used in the Intergroup trial probably necessitated the increased interval between chemotherapy and surgery (median 63 days in OE02 and 93 days in the Intergroup trial) which may have impacted on the percentage of patients undergoing resection in the trial: 80.3% in the chemotherapy arm and 95.6% in the surgery-alone arm in the Intergroup trial compared with 92% and 97%, respectively, in OE02. This in turn could explain the relatively poor survival in the experimental arm of the Intergroup trial. Either way, the OE02 trial was practice changing in the UK and some European countries and has led to the OE05 trial of neo-adjuvant CF (two cycles) versus neo-adjuvant ECX (three cycles) for patients with operable adenocarcinoma of the esophagus, which has recruited >400 patients.
Of note, the MAGIC trial [21] included 73 patients with adenocarcinoma of the lower esophagus and 58 patients with carcinoma of the OGJ and demonstrated no evidence of heterogeneity of treatment effect according to tumor site; therefore peri-operative ECF, or ECX are also reasonable options for these patients.
CRT
Before the publication of the OE02 data, a small randomized trial [27] had already established that surgery alone was not optimal treatment of adenocarcinoma of the esophagus. One hundred and thirteen patients were assigned to two cycles of neo-adjuvant CF-based CRT, or surgery alone and median overall survival was increased from a relatively poor 11 months in the control arm, to 16 months in the experimental arm (P = 0.01); comparable to the survival following neo-adjuvant chemotherapy in OE02 [26] . The treatment was well tolerated by most patients with 10% grade 3 and 3% grade 4 toxicity, however, mortality was higher in the combined modality arm with five deaths in the 58 patients, compared with two deaths in the control arm. This difference was not subjected to significance testing and the overall 6% in-hospital mortality rate is similar to the Intergroup [25] and OE02 [26] trials. A recent meta-analysis [28] evaluating neo-adjuvant CRT or chemotherapy showed benefits for both strategies in patients CRT was investigated as a neo-adjuvant approach in the management of squamous cell carcinoma (SCC) of the esophagus, to down-stage the disease, which is often locally advanced at presentation. In 1987, the SWOG-83037 trial [29] demonstrated that CRT with CF was feasible in patients with loco-regional disease, with a pathological complete response (pCR) in 17% of 106 evaluable patients, but the median survival of 12 months was disappointing. A phase II trial of CRT with 5-FU and MMC without surgery reported an encouraging median survival of 18 months in 57 patients with stage I/II disease who received radical treatment and 9 months and 11 months in the stage III and IV patients, respectively, who received palliative therapy [30] , suggesting a potential role for CRT alone. Similarly, in a randomized study of 135 patients with early-stage SCC of the esophagus, the Eastern Cooperative Oncology Group (ECOG) reported a statistically significant survival benefit from CRT with 5-FU and MMC, compared with radiotherapy alone [31] . A comparable 24 patients in the radiotherapy arm and 21 patients in the CRT arm proceeded to surgery, but the median survival was increased from 9.2 months to 14.8 months, respectively (P = 0.03), with improved survival regardless of whether the patients underwent surgery. The pCR rate was 15% of those resected. In the same year, a French group published results of a multicentre phase II trial of neo-adjuvant CRT with CF in patients with operable SCC of the esophagus [32] . The authors reported a pCR in 20% of patients who underwent surgery, which was a significant prognostic factor using the Cox model. These data, combined with a high operative mortality (9%) and median survival of 17 months for the cohort, led the group to hypothesize that CRT alone might be non-inferior to CRT then surgery. Therefore the group designed the FFCD 9102 trial, directly comparing CRT then surgery with CRT alone [33] . In this pivotal trial, 444 patients with operable thoracic esophageal carcinoma, mostly SCC, received CRT with CF and response was assessed after two cycles: 259 patients had responded and were randomized to receive either surgery or further CRT. The median survival was 17.7 months in those randomized to surgery and 19.3 months in those who continued CRT. The trial reached its primary endpoint of non-inferiority of 2-year survival (P = 0.03) and led to CRT alone being an accepted standard for patients with T3N0-1 SCC of the esophagus.
The Wales Cancer Trials Unit opened the SCOPE trial in 2007, a phase II/III trial designed for patients suitable for definitive CRT with cisplatin and capecitabine, who are randomized to receive CRT with or without the EGFR inhibitor, cetuximab. The addition of cetuximab is based on data in patients with locally advanced SCC of the head and neck [34] ; a statistically significant survival advantage was demonstrated in a trial of 424 patients, randomized to receive radiotherapy with or without cetuximab. The trial received criticism for using radiotherapy alone rather than CRT as the control arm, but provided evidence of safety and efficacy with radiotherapy. The SCOPE trial aims to recruit 420 patients and is powered to detect an overall survival advantage with the addition of cetuximab. The TKIs gefitinib and erlotinib are undergoing evaluation with CRT in phase II trials (Table 3) .
conclusions
Adjuvant chemotherapy for resected gastric cancer remains standard practice in Japan, whereas peri-operative chemotherapy or adjuvant CRT are both accepted standards in Western countries, with most UK centres favouring the MAGIC regimen of peri-operative ECF or ECX. Pre-operative chemotherapy and CRT have both shown survival benefits in resectable esophageal adenocarcinoma; but neo-adjuvant CF is the most common practice in the UK. Definitive CRT is as good as sequential use of CRT followed by surgery for many patients with SCC of the esophagus. At our institution, all patients with locally advanced SCC esophagus who are suitable for radical therapy will receive definitive CRT; with surgery reserved for patients with evidence of residual disease at their end-of-treatment assessments. Definitive CRT is also a reasonable option for patients with adenocarcinoma of the esophagus who are unsuitable for surgery.
All patients with gastro-esophageal cancer should have their case discussed in a multi-disciplinary environment and recommendations for therapy should be individualized, based on the patient's performance status and co-morbidities, before the recommendation is then discussed with the patient. Progress in the staging, early response evaluation, the development of novel targeted agents and predictive and prognostic biomarkers will allow treatment to be further tailored to the individual in the future. 
